Sarah Ouahoud1, Rutger J Jacobs1, Maikel P Peppelenbosch2, G M Fühler2, Jarom Heijmans3, Sander Diks4, Manon E Wildenberg3,5, Lukas J A C Hawinkels1, Liudmila L Kodach6, Philip W Voorneveld7, James C H Hardwick1. 1. Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands. 2. Department of Gastroenterology and Hepatology, Erasmus MC, Erasmus University Rotterdam, Rotterdam, the Netherlands. 3. Tytgat Institute for Liver & Intestinal Research, Academic Medical Center, Amsterdam, the Netherlands. 4. Department of Pediatric Oncology, University Medical Center Groningen, Groningen, the Netherlands. 5. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands. 6. Department of Pathology, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. 7. Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands. p.w.voorneveld@lumc.nl.
Abstract
BACKGROUND: Epidemiological studies and meta-analyses show an association between statin use and a reduced incidence of colorectal cancer (CRC). We have shown that statins act on CRC through bone morphogenetic protein (BMP) signalling, but the exact cellular targets and underlying mechanism of statin action remain elusive. In this study, we set out to assess the influence of statins on global cancer cell signalling by performing an array-based kinase assay using immobilised kinase substrates spanning the entire human kinome. METHODS: CRC cells with or without Lovastatin treatment were used for kinome analysis. Findings on kinome arrays were further confirmed by immunoblotting with activity-specific antibodies. Experiments in different CRC cell lines using immunoblotting, siRNA-mediated knockdown and treatment with specific BMP inhibitor Noggin were performed. The relevance of in vitro findings was confirmed in xenografts and in CRC patients treated with Simvastatin. RESULTS: Kinome analysis can distinguish between non-specific, toxic effects caused by 10 µM of Lovastatin and specific effects on cell signalling caused by 2 µM Lovastatin. Statins induce upregulation of PTEN activity leading to downregulation of the PI3K/Akt/mTOR signalling. Treatment of cells with the specific BMP inhibitor Noggin as well as PTEN knockdown and transfection of cells with a constitutively active form of AKT abolishes the effect of Lovastatin on mTOR phosphorylation. Experiments in xenografts and in patients treated with Simvastatin confirm statin-mediated BMP pathway activation, activation of PTEN and downregulation of mTOR signalling. CONCLUSIONS: Statins induce BMP-specific activation of PTEN and inhibition of PI3K/Akt/mTOR signalling in CRC.
BACKGROUND: Epidemiological studies and meta-analyses show an association between statin use and a reduced incidence of colorectal cancer (CRC). We have shown that statins act on CRC through bone morphogenetic protein (BMP) signalling, but the exact cellular targets and underlying mechanism of statin action remain elusive. In this study, we set out to assess the influence of statins on global cancer cell signalling by performing an array-based kinase assay using immobilised kinase substrates spanning the entire human kinome. METHODS: CRC cells with or without Lovastatin treatment were used for kinome analysis. Findings on kinome arrays were further confirmed by immunoblotting with activity-specific antibodies. Experiments in different CRC cell lines using immunoblotting, siRNA-mediated knockdown and treatment with specific BMP inhibitor Noggin were performed. The relevance of in vitro findings was confirmed in xenografts and in CRC patients treated with Simvastatin. RESULTS: Kinome analysis can distinguish between non-specific, toxic effects caused by 10 µM of Lovastatin and specific effects on cell signalling caused by 2 µM Lovastatin. Statins induce upregulation of PTEN activity leading to downregulation of the PI3K/Akt/mTOR signalling. Treatment of cells with the specific BMP inhibitor Noggin as well as PTEN knockdown and transfection of cells with a constitutively active form of AKT abolishes the effect of Lovastatin on mTOR phosphorylation. Experiments in xenografts and in patients treated with Simvastatin confirm statin-mediated BMP pathway activation, activation of PTEN and downregulation of mTOR signalling. CONCLUSIONS: Statins induce BMP-specific activation of PTEN and inhibition of PI3K/Akt/mTOR signalling in CRC.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; Tim Crowe; William J Sasiela; John Tsai; John Orazem; Raymond D Magorien; Charles O'Shaughnessy; Peter Ganz Journal: N Engl J Med Date: 2005-01-06 Impact factor: 91.245
Authors: Jenny N Poynter; Stephen B Gruber; Peter D R Higgins; Ronit Almog; Joseph D Bonner; Hedy S Rennert; Marcelo Low; Joel K Greenson; Gad Rennert Journal: N Engl J Med Date: 2005-05-26 Impact factor: 91.245
Authors: Chyke A Doubeni; Douglas A Corley; Virginia P Quinn; Christopher D Jensen; Ann G Zauber; Michael Goodman; Jill R Johnson; Shivan J Mehta; Tracy A Becerra; Wei K Zhao; Joanne Schottinger; V Paul Doria-Rose; Theodore R Levin; Noel S Weiss; Robert H Fletcher Journal: Gut Date: 2016-10-12 Impact factor: 23.059
Authors: Ronac Mamtani; James D Lewis; Frank I Scott; Tariq Ahmad; David S Goldberg; Jashodeep Datta; Yu-Xiao Yang; Ben Boursi Journal: PLoS Med Date: 2016-04-26 Impact factor: 11.069